Form 4 for BVS Bioventus Inc.

Accepted 2022-04-28 00:00:00 ET · period of report 2021-10-29 · accession 0000899243-22-015851 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2022-04-28	2021-10-29	BVS	Vizirgianakis Stavros G.	Dir	A - Grant	—	+2.78M	2.78M	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Common Stock	2021-10-29	A	A	2,780,923	—	2,780,923	D	—	—	(F1) Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each share of Misonix Inc. ("Misonix") common stock (a "Misonix Option") that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of the Company's Class A Common Stock, $0.001 par value per share ("Bioventus Shares"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.